Drug Trial Radar · NCT01544595
Extension Study of Secukinumab Prefilled Syringes in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Completing Preceding Psoriasis Phase III Studies With Secukinumab
Last checked: Nov 20, 2026Latest source record: Dec 20, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,147
Actual
Start
Jun 19, 2012
Primary completion
Jun 26, 2017
Study completion Jun 26, 2017
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Mar 6, 2012
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This was an extension study of secukinumab prefilled syringes in subjects with moderate to severe chronic plaque-type psoriasis completing preceding psoriasis phase III studies with secukinumab. Subjects on secukinumab at the end of treatment period in phase III studies (e.g., ongoing CAIN457A2302 and CAIN457A2303 and potentially other secukinumab phase III studies) were eligible to join this extension study. This extension study was planned to collect an additional 2 years of long-term efficacy, safety, and tolerability data of secukinumab in either continuous or interrupted therapy (randomized withdrawal period) in subjects showing at least partial response to secukinumab and completing treatment period on secukinumab in previous phase III studies. In this extension study, the prefilled syringe (PFS) liquid formulation of secukinumab were used.
Conditions
- Moderate to Severe Plaque-type Psoriasis
Interventions
Secukinumab (AIN457)Drug
Secukinumab is a new type of psoriasis medication called a human monoclonal antibody. Monoclonal antibodies are proteins that recognize and bind to unique proteins that your body produces. Secukinumab binds and reduces the activity of a cytokine (a "messenger" protein in the body) called Interleukin 17 (IL-17). IL-17 is believed to be partly responsible for inflammation (pain, swelling, redness). Researchers believe that IL-17 causes symptoms of plaque-type psoriasis like plaques and scales. A product that targets IL-17 therefore may help to relieve these symptoms and conditions.
PlaceboDrug
Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent of Participants With Loss of Psoriasis Area and Severity Index (PASI) 75 Response up to Week 68Time frame: At week 68 (16 weeks after week 52)
Locations
182 sites in 26 countries. Site status is shown where the registry gives one.
Novartis Investigative Site
Birmingham, Alabama
Novartis Investigative Site
Birmingham, Alabama
Novartis Investigative Site
Phoenix, Arizona
Novartis Investigative Site
Phoenix, Arizona
Novartis Investigative Site
Los Angeles, California
Novartis Investigative Site
Oceanside, California
Novartis Investigative Site
Pasadena, California
Novartis Investigative Site
San Diego, California
Novartis Investigative Site
San Diego, California
Novartis Investigative Site
Colorado Springs, Colorado
Novartis Investigative Site
Snellville, Georgia
Novartis Investigative Site
Indianapolis, Indiana
Novartis Investigative Site
Topeka, Kansas
Novartis Investigative Site
Louisville, Kentucky
Novartis Investigative Site
Louisville, Kentucky
Novartis Investigative Site
Ann Arbor, Michigan
Novartis Investigative Site
Omaha, Nebraska
Novartis Investigative Site
New York, New York
Novartis Investigative Site
Rochester, New York
Novartis Investigative Site
High Point, North Carolina
Novartis Investigative Site
Warren, Ohio
Novartis Investigative Site
Oregon City, Oregon
Novartis Investigative Site
Portland, Oregon
Novartis Investigative Site
Portland, Oregon
Novartis Investigative Site
Duncansville, Pennsylvania
Novartis Investigative Site
Philadelphia, Pennsylvania
Novartis Investigative Site
Johnston, Rhode Island
Novartis Investigative Site
Charleston, South Carolina
Novartis Investigative Site
Kingsport, Tennessee
Novartis Investigative Site
Nashville, Tennessee
Novartis Investigative Site
Austin, Texas
Novartis Investigative Site
Dallas, Texas
Novartis Investigative Site
Dallas, Texas
Novartis Investigative Site
Houston, Texas
Novartis Investigative Site
San Antonio, Texas
Novartis Investigative Site
Salt Lake City, Utah
Novartis Investigative Site
Norfolk, Virginia
Novartis Investigative Site
Buenos Aires, Argentina
Novartis Investigative Site
Mendoza, Argentina
Novartis Investigative Site
CABA, Buenos Aires, Argentina
Showing 40 of 182 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.